Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials

Statistics in Biosciences

Volumn 8, Issue 1, 2016, Pages 159-180

  Xu, Yanxun ^a   Trippa, Lorenzo ^b   Müller, Peter ^a   Ji, Yuan ^c,d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adaptive designs; Bayesian inference; Biomarkers; Posterior; Subgroup identification; Targeted therapies

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; COMPUTER SIMULATION; DECISION MAKING; HISTOGRAM; HUMAN; MATHEMATICAL MODEL; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STUDY DESIGN; SUBGROUP BASED ADAPTIVE DESIGN;

EID: 84904229781     PISSN: 18671764     EISSN: 18671772     Source Type: Journal    
DOI: 10.1007/s12561-014-9117-1     Document Type: Article

References (33)

1. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009
2. Snijders A, Nowak N, Segraves R, Blackwood S, Brown N et al (1998) Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 29:263–264
3. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536
4. Curtis C, Shah S, Chin SF, Turashvili G, Rueda O, Dunning M et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352
5. Baladandayuthapani V, Ji Y, Talluri R, Nieto-Barajas L, Morris J (2010) Bayesian random segmentation models to identify shared copy number aberrations for array CGH data. J Am Stat Assoc 105: 1358–1375
6. Wang Z, Zang C, Rosenfeld J, Schones D, Barski A, Cuddapah S et al (2008) Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40:897–903
7. Barski A, Zhao K (2009) Genomic location analysis by ChIP-Seq. J Cell Biochem 107:11–18
8. Mitra R, Müller P, Shoudan L, Yue L, Ji Y (2013) A bayesian graphical model for chip-seq data on histone modifications. J Am Stat Assoc 108(501):69–80
9. Hudis CA (2007) Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51
10. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404):532–536
11. Simon R, Maitournam A (2004) Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10(20):6759–6763
12. Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23(9):2020–2027
13. Maitournam A, Simon R (2005) On the efficiency of targeted clinical trials. Stat Med 24(3):329–339
14. Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102(3):152–160
15. Simon Richard (2010) Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Pers Med 7(1):33–47
16. Mandrekar SJ, Sargent DJ (2010) Predictive biomarker validation in practice: lessons from real trials. Clin Trials 7(5):567–573
17. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Sanjay G et al (2011) The battle trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44–53
18. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-spy 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86(1): 97–100
19. Yin G, Chen N, Lee JJ (2012) Phase ii trial design with bayesian adaptive randomization and predictive probability. J R Stat Soc Ser C Appl Stat 61(2):219–235
20. Gu X, Lee JJ (2010) A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol 10(1):48
21. Zhu H, Hu F, Zhao H (2013) Adaptive clinical trial designs to detect interaction between treatment and a dichotomous biomarker. Can J Stat 41:1–15
22. Ruberg SJ, Chen L, Wang Y (2010) The mean does not mean as much anymore: finding sub-groups for tailored therapeutics. Clin Trials 7(5):574–583
23. Foster JC, Taylor JMG, Ruberg SJ (2011) Subgroup identification from randomized clinical trial data. Stat Med 30(24):2867–2880
24. Loredo T (2003) Bayesian adaptive exploration in a nutshell. Stat Probl Part Phys Astrophys Cosmol 1:162–165
25. Kruschke J (2008) Bayesian approaches to associative learning: from passive to active learning. Learn Behav 36:210–226
26. Fedorov VV, Leonov SL (2013) Optimal design for nonlinear response models. CRC Press
27. Chipman HA, George EI, McCulloch RE (1998) Bayesian cart model search. J Am Stat Assoc 93(443):935–948
28. Denison DGT, Mallick BK, Smith AFM (1998) A bayesian cart algorithm. Biometrika 85(2):363–377
29. Gelfand AE, Ghosh SK (1998) Model choice: a minimum posterior predictive loss approach. Biometrika 85(1):1–11
30. Raiffa H, Schlaifer R (1961) Applied statistical decision theory. Harvard Business School Publications, Boston, MA
31. Thall PF, Wathen JK (2007) Practical bayesian adaptive randomisation in clinical trials. Eur J Cancer 43(5):859–866
32. Medvedovic M, Yeung KY, Bumgarner RE (2004) Bayesian mixture model based clustering of replicated microarray data. Bioinformatics 20(8):1222–1232
33. Dahl DB (2006) Model-based clustering for expression data via a dirichlet process mixture model. In: Do K-A, Mueller P, Vannucci, M (eds) Bayesian inference for gene expression and proteomics, pp 201–218